

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 2, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

DUSA Pharmaceuticals, Inc.

File No. 1-31533 - CF#33311

DUSA Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 11, 2004 and a Form 10-K filed on March 6, 2012.

Based on representations by DUSA Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit	to Form	Filed on	Confidential Treatment Granted
10(a)	10-Q	August 11, 2004	through December 31, 2017
10(h)	10-K	March 6, 2012	through December 31, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent. J Fields
Secretary